Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
School of Medicine, Tongji University, Shanghai 200092, China.
Chin Med J (Engl). 2022 May 20;135(10):1203-1212. doi: 10.1097/CM9.0000000000001981.
Immunotherapy that targets checkpoints, especially programmed cell death protein 1 and programmed cell death ligand 1, has revolutionized cancer therapy regimens. The overall response rate to mono-immunotherapy, however, is limited, emphasizing the need to potentiate the efficacy of these regimens. The functions of immune cells are modulated by multiple stimulatory and inhibitory molecules, including lymphocyte activation gene 3 (LAG-3). LAG-3 is co-expressed together with other inhibitory checkpoints and plays key roles in immune suppression. Increasing evidence, particularly in the last 5 years, has shown the potential of LAG-3 blockade in anti-tumor immunity. This review provides an update on the biological properties and clinical applications of LAG-3 in cancers.
免疫疗法靶向检查点，特别是程序性细胞死亡蛋白 1 和程序性细胞死亡配体 1，已经彻底改变了癌症治疗方案。然而，单免疫疗法的总体反应率有限，这强调了需要增强这些方案的疗效。免疫细胞的功能受到多种刺激和抑制分子的调节，包括淋巴细胞激活基因 3（LAG-3）。LAG-3 与其他抑制性检查点共同表达，在免疫抑制中发挥关键作用。越来越多的证据，特别是在过去 5 年中，表明 LAG-3 阻断在抗肿瘤免疫中的潜力。本综述提供了关于 LAG-3 在癌症中的生物学特性和临床应用的最新信息。
